MXPA97004127A - Nuevos derivados de bencimidazol con actividad antihistaminica. - Google Patents
Nuevos derivados de bencimidazol con actividad antihistaminica.Info
- Publication number
- MXPA97004127A MXPA97004127A MXPA97004127A MX9704127A MXPA97004127A MX PA97004127 A MXPA97004127 A MX PA97004127A MX PA97004127 A MXPA97004127 A MX PA97004127A MX 9704127 A MX9704127 A MX 9704127A MX PA97004127 A MXPA97004127 A MX PA97004127A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- group
- base
- addition salt
- compound according
- Prior art date
Links
- 230000001387 anti-histamine Effects 0.000 title abstract description 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract description 3
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 abstract description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract description 2
- -1 4,4-dimethyl-2-oxazolinyl Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229910000103 lithium hydride Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES09601236A ES2124167B1 (es) | 1996-06-04 | 1996-06-04 | Nuevos derivados del bencimidazol con actividad antihistaminica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA97004127A true MXPA97004127A (es) | 2005-07-25 |
Family
ID=8295035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA97004127A MXPA97004127A (es) | 1996-06-04 | 1997-06-04 | Nuevos derivados de bencimidazol con actividad antihistaminica. |
Country Status (27)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2332178A1 (en) | 1998-07-01 | 2000-01-13 | Takeda Chemical Industries, Ltd. | Retinoid-associated receptor function regulating agent |
| JP3432800B2 (ja) | 1998-11-27 | 2003-08-04 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 置換ベンゾイミダゾールおよびそのｐａｒｐ阻害剤としての使用 |
| ES2151442B1 (es) * | 1999-01-11 | 2001-07-01 | Espanola Prod Quimicos | Nuevo derivado del bencenoetanol. |
| US6826561B2 (en) | 2000-05-22 | 2004-11-30 | Broadcom Corporation | Method and apparatus for performing a binary search on an expanded tree |
| US7612095B2 (en) * | 2002-04-19 | 2009-11-03 | Faes Farma, S.A. | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid |
| RU2288917C2 (ru) * | 2002-04-19 | 2006-12-10 | Фаэс Фарма, С.А. | Полиморф 4-[2-[4-[1-(2-этоксиэтил)-1h-бензимидазол-2-ил]-1-пиперидинил]этил]-альфа, альфа-диметилбензолуксусной кислоты, способ его получения, фармацевтический препарат на его основе и его применение |
| US7727992B2 (en) * | 2002-06-13 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US20070188330A1 (en) * | 2006-01-24 | 2007-08-16 | Morhard Robert C | System and method for detecting, monitoring, tracking and identifying explosive materials using ID marks |
| US7247623B2 (en) * | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| WO2009102155A2 (en) * | 2008-02-12 | 2009-08-20 | Yuhan Corporation | Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds |
| JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体 |
| CN102675101B (zh) * | 2012-05-16 | 2014-01-29 | 王蕾 | 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法 |
| CZ307500B6 (cs) | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
| MX366869B (es) * | 2013-03-15 | 2019-07-29 | Hercules Inc | Composición y método para producir composiciones para el cuidado personal con propiedades de deposición mejoradas. |
| CN103214455B (zh) * | 2013-03-30 | 2018-08-31 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀的制备方法 |
| CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
| WO2014188453A2 (en) * | 2013-05-24 | 2014-11-27 | Msn Laboratories Private Limited | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid |
| CN103351380B (zh) * | 2013-06-30 | 2019-01-22 | 北京万全德众医药生物技术有限公司 | 一种制备比拉斯汀的方法 |
| CN104447683A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种稳定的比拉斯汀化合物 |
| CN103896915A (zh) * | 2014-04-01 | 2014-07-02 | 中国药科大学 | 苯并咪唑类衍生物、其制备方法及其在医药上的应用 |
| EP3040334A1 (en) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | New benzimidazole derivatives as antihistamine agents |
| CN106349214B (zh) * | 2015-07-13 | 2020-11-03 | 南京长澳医药科技有限公司 | 一种比拉斯汀杂质的制备方法 |
| LT3327012T (lt) * | 2015-07-24 | 2021-09-10 | Urquima, S.A. | Bilastino kristalinės formos ir jų gamybos būdai |
| CN105272977A (zh) * | 2015-09-19 | 2016-01-27 | 万全万特制药江苏有限公司 | 一种制备比拉斯汀中间体的方法 |
| EP3170816A1 (en) | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
| EP3170817A1 (en) | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
| WO2017167949A1 (en) | 2016-04-01 | 2017-10-05 | Krka, D.D., Novo Mesto | Crystalline forms of bilastine |
| EP3452462A4 (en) * | 2016-05-05 | 2019-10-23 | MSN Laboratories Private Limited, R&D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
| CN107365298A (zh) * | 2017-03-14 | 2017-11-21 | 罗欣生物科技（上海）有限公司 | 一种2‑甲基‑2’‑苯基丙酸衍生物的制备方法 |
| CN109456316A (zh) * | 2017-09-06 | 2019-03-12 | 万全万特制药江苏有限公司 | 一种比拉斯汀杂质的制备方法 |
| EP3453384B1 (en) | 2017-09-07 | 2020-05-27 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine |
| PL3681475T3 (pl) | 2017-10-16 | 2021-07-05 | Faes Farma, S.A. | Wodne kompozycje zawierające bilastynę i mometazon |
| ES2835287T3 (es) | 2017-12-18 | 2021-06-22 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio |
| ES2773756R1 (es) | 2017-12-18 | 2021-04-12 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua |
| PT3740191T (pt) | 2018-01-18 | 2021-07-09 | Faes Farma Sa | Composições oftálmicas compreendendo bilastina, uma beta-ciclodextrina e pelo menos um agente gelificante |
| CN109081827A (zh) * | 2018-11-06 | 2018-12-25 | 北京天弘天达医药科技股份有限公司 | 一种比拉斯汀的制备方法及应用 |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| EP4188339A1 (en) | 2020-07-30 | 2023-06-07 | Faes Farma, S.A. | Decongestant drug delivery system |
| CN112110893A (zh) * | 2020-10-28 | 2020-12-22 | 山东齐环医药科技有限公司 | 一种比拉斯汀的制备方法 |
| US20230414597A1 (en) | 2020-11-18 | 2023-12-28 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising an antihistamine compound |
| CA3200779A1 (en) | 2020-12-23 | 2022-06-30 | Strusi ORAZIO LUCA | A non-micronized bilastine composition |
| PE20251070A1 (es) | 2022-02-17 | 2025-04-10 | Faes Farma Sa | Composicion de bilastina para la administracion parenteral una vez al dia |
| WO2024224308A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine free of cyclodextrins |
| WO2024224326A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8904174D0 (en) * | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
| WO1991016313A1 (en) * | 1990-04-13 | 1991-10-31 | Smithkline Beecham Corporation | Substituted benzimidazoles |
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| EP1688142A1 (en) * | 1992-08-03 | 2006-08-09 | Sepracor Inc. | Terfenadine carboxylate and the treatment of dermal irritation |
| CA2362337C (en) * | 1993-06-25 | 2005-08-02 | Merrell Pharmaceuticals Inc. | Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |
-
1996
- 1996-06-04 ES ES09601236A patent/ES2124167B1/es not_active Expired - Fee Related
-
1997
- 1997-06-03 PT PT97500099T patent/PT818454E/pt unknown
- 1997-06-03 DE DE69728608T patent/DE69728608T2/de not_active Expired - Lifetime
- 1997-06-03 EP EP97500099A patent/EP0818454B1/en not_active Expired - Lifetime
- 1997-06-03 AT AT97500099T patent/ATE264317T1/de active
- 1997-06-03 DK DK97500099T patent/DK0818454T3/da active
- 1997-06-03 AU AU24672/97A patent/AU725700B2/en not_active Expired
- 1997-06-03 DE DE122011000006C patent/DE122011000006I1/de active Pending
- 1997-06-03 CA CA002206754A patent/CA2206754C/en not_active Expired - Lifetime
- 1997-06-03 ZA ZA9704893A patent/ZA974893B/xx unknown
- 1997-06-03 RU RU97108980/04A patent/RU2182150C2/ru active
- 1997-06-03 HR HR970307A patent/HRP970307B1/xx not_active IP Right Cessation
- 1997-06-03 NO NO19972525A patent/NO313195B1/no not_active IP Right Cessation
- 1997-06-03 SI SI9730652T patent/SI0818454T1/xx unknown
- 1997-06-04 JP JP16201097A patent/JP4218991B2/ja not_active Expired - Lifetime
- 1997-06-04 CZ CZ19971723A patent/CZ289278B6/cs not_active IP Right Cessation
- 1997-06-04 BR BR9703276-0A patent/BR9703276A/pt not_active IP Right Cessation
- 1997-06-04 TR TR97/00464A patent/TR199700464A3/tr unknown
- 1997-06-04 HU HU9700997A patent/HU227598B1/hu active Protection Beyond IP Right Term
- 1997-06-04 PL PL97320358A patent/PL188908B1/pl unknown
- 1997-06-04 MX MXPA97004127A patent/MXPA97004127A/es active IP Right Grant
- 1997-06-04 IN IN1498DE1997 patent/IN186319B/en unknown
- 1997-06-04 CN CN97114905A patent/CN1105716C/zh not_active Expired - Lifetime
- 1997-06-04 US US08/868,743 patent/US5877187A/en not_active Expired - Lifetime
- 1997-06-05 AR ARP970102441A patent/AR008386A1/es active IP Right Grant
- 1997-07-22 TW TW086110371A patent/TW438794B/zh not_active IP Right Cessation
-
2011
- 2011-03-22 LU LU91798C patent/LU91798I2/fr unknown
- 2011-05-24 NO NO2011008C patent/NO2011008I2/no unknown
- 2011-07-08 FR FR11C0023C patent/FR11C0023I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA97004127A (es) | Nuevos derivados de bencimidazol con actividad antihistaminica. | |
| US4661499A (en) | 2-[(substituted)-phenoxymethyl]quinolines | |
| RU2306314C2 (ru) | Производные 6-амино-морфинана и их применение | |
| PT88944B (pt) | Processo para a preparacao de novos derivados de benzocilclohepteno e de composicoes farmaceuticas que as contem | |
| PT91968B (pt) | Processo para a preparacao de novos piperidinil-benzimidazois e de composicoes farmaceuticas que os contem | |
| IE63662B1 (en) | Salts of azelastine having improved solubility | |
| CN100586434C (zh) | 止痒剂 | |
| WO1990012574A1 (en) | Dopamine agonist compounds | |
| JPH0625091B2 (ja) | ジヒドロジベンゾシクロヘプチリデン―エチルアミン誘導体その製法ならびに医薬組成物 | |
| EP0089061B1 (en) | 8-substituted pyrrolizidine derivatives and use thereof | |
| FI59984C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara alfa-alkylindanaettiksyraderivat | |
| JPS62169791A (ja) | ピロロ〔１，２−ａ〕〔４，１〕ベンゾオキサゼピン誘導体 | |
| GB1590155A (en) | Cis-4a-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-2-pyrindines and pharmaceutical compositions containing them | |
| US3452030A (en) | 4-(n-isobutyrylanilino)-1-benzylpiperidine | |
| KR100494448B1 (ko) | 항히스타민활성을가지는신규한벤조이미다졸유도체 | |
| JP2524420B2 (ja) | ピペリジン誘導体及びそれらを有効成分とする抗潰瘍剤 | |
| US3903093A (en) | 2-({62 -Alkyl thioethyl)-6,7-benzomorphans | |
| IL34468A (en) | Acidic salt salts of the history of indonopyridine, their preparation and pharmaceutical preparations containing them | |
| US3763184A (en) | Pharmaceutically active pyrrolidino naphthothiophenes | |
| JPS61191678A (ja) | うつ病治療剤 | |
| US3966939A (en) | Novel 2-substituted 6,7-benzomorphan derivatives and salts thereof in analgesic compositions | |
| AU4564593A (en) | New analgesic and nootropic drugs | |
| JPS5917112B2 (ja) | 新規ベンゾモルフアン誘導体 | |
| JPS6135177B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| KR810000583B1 (ko) | 4a-아릴-옥타하이드로-1H-2-피린딘류의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration |